본문 바로가기

바이오스펙테이터

기사본문

NeoImmuneTech, 'NT-I7' Four differentiation-based IO development strategies

입력 2018-12-06 04:28 수정 2019-01-28 21:29

바이오스펙테이터 Sungmin Kim 기자

이 기사는 '프리미엄 뉴스서비스 BioS+' 기사입니다.

▲양세환 네오이뮨텍 대표

NT-I7 (GX-I7, HyLeukin-7), the key pipeline of NeoImmuneTech, is long-acting Interleukin-7 (IL-7). NT-I7 increases the number of T-cells, and improves T-cell function. Recently, increasing attention is being shown to various roles of IL-7 in the anti-cancer and immunity fields, including immune checkpoint inhibitor. From next year, Proof of Concept (PoC) will be commenced in patients with cancer, while post-clinical development for commercialization is planned in 2020.”

Yang Se-hwan, the CEO of NeoImmuneTech, introduced the distinctiveness of NT-I7, and its development strategy. CEO Yang established NeoImmuneTech, the clinical and business development-driven company, in Rockville, Maryland, USA, in 2014, and adopted iL-7 combined with hyFc, one of Genexin’s pipelines.

NT-I7 increases “activity and half-life to 100 hours” compared to previous IL-7

He said “IL-7 plays a mothering role for T-lymphocytes in the immune system”. IL-7 is involved in the development, homeostasis, and survival of T-lymphocytes. In rat, IL-7R knock-out causes thymic atrophy. It also discontinues T-cell development, and causes severe lymphopenia. In contrast, administration of IL-7 in rat or human increases the number of T-cells, and recovers T-cell immune system....

'프리미엄 뉴스서비스 BioS+'는 독자들에게 가치(value)있는 기사를 제공합니다.
추가내용은 유료회원만 이용할 수 있습니다.
회원이시면 로그인 해주시고, 회원가입을 원하시면 클릭 해주세요.
카카오스토리로 기사 공유하기